Li Jiajing, Liu Qi, Zhang Ting, Du Qian
The Diagnostics Laboratory, Affiliated Hospital to Zunyi Medical University, Zunyi, Guizhou, 563000, People's Republic of China.
Affiliated Hospital to Zunyi Medical University, Zunyi, Guizhou, 563000, People's Republic of China.
Cancer Manag Res. 2024 Nov 14;16:1597-1608. doi: 10.2147/CMAR.S478426. eCollection 2024.
Hepatocellular carcinoma (HCC), a prevalent and aggressive form of cancer, poses significant challenges due to its limited therapeutic options. This study aims to leverage multi-omics data from liver cancer to identify potential therapeutic targets for HCC.
We employed an integrative approach by analyzing various omics datasets related to liver cancer. Through comprehensive data mining and analysis, we identified key genes that are significantly associated with HCC. To gain insights into their biological roles and underlying mechanisms, we constructed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway networks. Specifically, we focused on genes that exhibited high expression levels in HCC and were correlated with poor patient prognosis. Among these, CDK1 and DLGAP5 emerged as promising candidates and were further investigated for their potential involvement in tumor immune cell infiltration and HCC progression.
Our analysis revealed that CDK1 and DLGAP5 are highly expressed in HCC tissues compared to normal liver tissues, and their elevated expression is associated with unfavorable clinical outcomes. Furthermore, through GO and KEGG pathway analyses, we found that these genes are implicated in critical biological processes and signaling pathways relevant to HCC pathogenesis. Notably, CDK1 and DLGAP5 were shown to be associated with tumor immune cell infiltration, suggesting their potential role in modulating the tumor microenvironment and promoting HCC progression.
These findings provide valuable insights into the development of novel therapeutic approaches for HCC.
肝细胞癌（HCC）是一种常见且侵袭性强的癌症形式，因其治疗选择有限而带来重大挑战。本研究旨在利用肝癌的多组学数据来识别HCC的潜在治疗靶点。
我们采用综合方法，分析了与肝癌相关的各种组学数据集。通过全面的数据挖掘和分析，我们确定了与HCC显著相关的关键基因。为深入了解它们的生物学作用和潜在机制，我们构建了基因本体（GO）和京都基因与基因组百科全书（KEGG）通路网络。具体而言，我们聚焦于在HCC中高表达且与患者预后不良相关的基因。其中，细胞周期蛋白依赖性激酶1（CDK1）和5-磷酸二酯酶激活蛋白（DLGAP5）成为有前景的候选基因，并进一步研究它们在肿瘤免疫细胞浸润和HCC进展中的潜在作用。
我们的分析表明，与正常肝组织相比，CDK1和DLGAP5在HCC组织中高表达，其表达升高与不良临床结果相关。此外，通过GO和KEGG通路分析，我们发现这些基因参与了与HCC发病机制相关的关键生物学过程和信号通路。值得注意的是，CDK1和DLGAP5与肿瘤免疫细胞浸润相关，表明它们在调节肿瘤微环境和促进HCC进展中的潜在作用。
这些发现为HCC新型治疗方法的开发提供了有价值的见解。
